[go: up one dir, main page]

WO2005033089A1 - Salt of 6-(1, 3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid with n, n-dimethyl-imidodicarbonimidic diamide - Google Patents

Salt of 6-(1, 3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid with n, n-dimethyl-imidodicarbonimidic diamide Download PDF

Info

Publication number
WO2005033089A1
WO2005033089A1 PCT/IN2003/000329 IN0300329W WO2005033089A1 WO 2005033089 A1 WO2005033089 A1 WO 2005033089A1 IN 0300329 W IN0300329 W IN 0300329W WO 2005033089 A1 WO2005033089 A1 WO 2005033089A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
isobenzofuranyl
dihydro
oxo
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2003/000329
Other languages
French (fr)
Inventor
Sambasivam Ganesh
Goutam Das
Shankara Rao Arvind Atignal
Kiran Mazumdar-Shaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocon Ltd
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Priority to AU2003272083A priority Critical patent/AU2003272083A1/en
Priority to PCT/IN2003/000329 priority patent/WO2005033089A1/en
Publication of WO2005033089A1 publication Critical patent/WO2005033089A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Definitions

  • 6-(l,3 ⁇ dihydro-4-hydroxy-6-methoxy-7-methyl-3- oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid, sodium salt or its 2-ethyl morphoiino derivative is used as immunosuppressants.
  • 6- (l,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5- isobenzofuranyl)-4-methyl-4-hexenoic acid is generally administered as a sodium salt or 2-ethyl morphoiino derivative so that active free acid is made available for absorption.
  • Antihyperglycemic agents are used for treatment of diabetes.
  • N, N- dimethyl- imidodicarbonimidic diamide is used for treatment of Non-insulin dependent diabetes mellitus (NIDDM).
  • N, N-dimethyl- imidodicarbonimidic diamide is generally administered a HCI salt.
  • the present inventions discloses a novel compound of formula I which can be simultaneously used as an immunosuppressant and antihyperglycemic agent for the treatment of diabetic nephropathy.
  • SUMMARY OF THE INVENTION The present invention discloses a novel compound of formula I. The compound can be simultaneously used as an immunosuppressant and antihyperglycemic agent for the treatment of diabetic nephropathy.
  • FORMULA I The important embodiment of the invention is that the compound of formula I, wherein the two drug molecules form a mutual salt which can be called X N, N-dimethyl- imidodicarbonimidic diamide salt of 6-(l,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3- oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid.
  • the invention discloses the compound of formula I, wherein the 6-(l,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5- isobenzofuranyl)-4-methyl-4-hexenoic acid is an immunosuppressive drug and N, N-dimethyl- imidodicarbonimidic diamide is an antihyperglycemic drug.
  • the compound of formula I is formed when the two compounds are treated with each other under suitable conditions to form a non-covalent bond between the carboxylic group of 6- (l,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5- isobenzofuranyl)-4-methyl-4-hexenoic acid and nitrogen of N, N- dimethyl- imidodicarbonimidic diamide.
  • the non- covalent bond thus formed is an ionic bond between 6-(l,3- dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)- 4-methyl-4-hexenoic acid and N, N-dimethyl- imidodicarbonimidic diamide.
  • the compound of formula I is a mutual salt of 6-(l,3- dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)- 4-methyl-4-hexenoic acid and N, N-dimethyl- imidodicarbonimidic diamide.
  • compound of formula I retain the free acid form of 6-(l,3-dihydro- 4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl- 4-hexenoic acid.
  • Compound of formula I have the extra advantage of delivering the free acid form of 6-( ⁇ ,3-dihydro-4-hydroxy-6- methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid without employing any metal cation. Unlike prior art, compound of formula I delivers N, N- dimethyl- imidodicarbonimidic diamide free-base without employing any other acid salt like hydrochloride salt.
  • the following non-limiting examples illustrate the inventors' preferred method for preparing the compound of the invention.
  • reaction mixture was chilled (10-15° C) and filtered to afford the mutual salt of 6-(l,3-dihydro-4-hydroxy-6- methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic5 acid and N, N-dimethyl- imidodicarbonimidic diamide.
  • Example 2 To a solution of 6-(l,3-dihydro-4-hydroxy-6-methoxy-7- methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid (10 g, 0.03 mol) in isobutyl acetate (75 ml), N, N-dimethyl-o imidodicarbonimidic diamide free base (4.0 g, 0.03 mol) was added and stirred.
  • reaction mixture was chilled (10-15° C) and filtered o afford the mutual salt of 6-(l,3-dihydro-4-hydroxy-6-methoxy-7- methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid and N, N-dimethyl- imidodicarbonimidic diamide.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A novel compound of formula (I), a mutual salt of 6-(1,3­-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)­-4-methyl-4-hexenoic acid and N, N-dimethyl- imidodicarbonimidic diamide, is disclosed. The compound of formula (I) can be simultaneously used as an immunosuppressant and anti hyperglycemic agent for the treatment of diabetic nephropathy.

Description

TITLE OF THE INVENTION SALT OF 6-(l,3-DIHYDRO-4-HYDROXY-6-METHOXY- 7-METHYL-3-OXO-5-ISOBENZOFURANYL)-4-METHYL-4- HEXENOIC ACID WITH N, N-DIMETHYL- IMIDODICARBONIMIDIC DIAMIDE FIELD OF THE INVENTION This invention relates to a novel compound of formula I, which can be simultaneously used as an immunosuppressant and antihyperglycemic agent for the treatment of diabetic nephropathy. BACKGROUND OF THE INVENTION Drugs like 6-(l,3~dihydro-4-hydroxy-6-methoxy-7-methyl-3- oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid, sodium salt or its 2-ethyl morphoiino derivative is used as immunosuppressants. 6- (l,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5- isobenzofuranyl)-4-methyl-4-hexenoic acid is generally administered as a sodium salt or 2-ethyl morphoiino derivative so that active free acid is made available for absorption. Antihyperglycemic agents are used for treatment of diabetes. N, N- dimethyl- imidodicarbonimidic diamide is used for treatment of Non-insulin dependent diabetes mellitus (NIDDM). N, N-dimethyl- imidodicarbonimidic diamide is generally administered a HCI salt. The present inventions discloses a novel compound of formula I which can be simultaneously used as an immunosuppressant and antihyperglycemic agent for the treatment of diabetic nephropathy. SUMMARY OF THE INVENTION The present invention discloses a novel compound of formula I. The compound can be simultaneously used as an immunosuppressant and antihyperglycemic agent for the treatment of diabetic nephropathy. FORMULA I
Figure imgf000003_0001
It is mutual salt of two drugs viz. 6-(l,3-dihydro-4-hydroxy-6- methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid and N, N-dimethyl- imidodicarbonimidic diamide. DETAILED DESCRIPTION OF THE INVENTION The present invention discloses a novel compound of formula I, which can be simultaneously used as an immunosuppressant and antihyperglycemic agent for the treatment of diabetic nephropathy.
Figure imgf000003_0002
FORMULA I The important embodiment of the invention is that the compound of formula I, wherein the two drug molecules form a mutual salt which can be called XN, N-dimethyl- imidodicarbonimidic diamide salt of 6-(l,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3- oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid. The invention discloses the compound of formula I, wherein the 6-(l,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5- isobenzofuranyl)-4-methyl-4-hexenoic acid is an immunosuppressive drug and N, N-dimethyl- imidodicarbonimidic diamide is an antihyperglycemic drug. The compound of formula I is formed when the two compounds are treated with each other under suitable conditions to form a non-covalent bond between the carboxylic group of 6- (l,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5- isobenzofuranyl)-4-methyl-4-hexenoic acid and nitrogen of N, N- dimethyl- imidodicarbonimidic diamide. Preferably, the non- covalent bond thus formed is an ionic bond between 6-(l,3- dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)- 4-methyl-4-hexenoic acid and N, N-dimethyl- imidodicarbonimidic diamide. The compound of formula I is a mutual salt of 6-(l,3- dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)- 4-methyl-4-hexenoic acid and N, N-dimethyl- imidodicarbonimidic diamide. Like any metal salt of 6-(l,3-dihydro-4-hydroxy-6-methoxy-7- methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid, compound of formula I retain the free acid form of 6-(l,3-dihydro- 4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl- 4-hexenoic acid. Compound of formula I have the extra advantage of delivering the free acid form of 6-(ϊ,3-dihydro-4-hydroxy-6- methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid without employing any metal cation. Unlike prior art, compound of formula I delivers N, N- dimethyl- imidodicarbonimidic diamide free-base without employing any other acid salt like hydrochloride salt. The following non-limiting examples illustrate the inventors' preferred method for preparing the compound of the invention. EXAMPLES Example 1 To a solution of 6-(l,3-dihydro-4-hydroxy-6-methoxy-7- methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid (5 g, 0.015 mol) in ethyl acetate (75 ml), N, N-dimethyl- imidodicarbonimidic diamide free base (2.0 g, 0.015 mol) was added and stirred. The reaction mixture was chilled (10-15° C) and filtered to afford the mutual salt of 6-(l,3-dihydro-4-hydroxy-6- methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic5 acid and N, N-dimethyl- imidodicarbonimidic diamide. Example 2 To a solution of 6-(l,3-dihydro-4-hydroxy-6-methoxy-7- methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid (10 g, 0.03 mol) in isobutyl acetate (75 ml), N, N-dimethyl-o imidodicarbonimidic diamide free base (4.0 g, 0.03 mol) was added and stirred. The reaction mixture was chilled (10-15° C) and filtered o afford the mutual salt of 6-(l,3-dihydro-4-hydroxy-6-methoxy-7- methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid and N, N-dimethyl- imidodicarbonimidic diamide.

Claims

We claim
1. A compound of formula I
Figure imgf000007_0001
FORMULA I
2. A compound of formula I as in claim 1, wherein the compound is a mutual salt of 6-(l,3-dihydro-4-hydroxy-6- methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4- hexenoic acid and N, N-dimethyl- imidodicarbonimidic diamide. 3. A process of preparing a compound of formula I comprising of stirring 6-(l,
3-dihydro-4-hydroxy-6-methoxy-7-methyl-3- oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid free acid with N,N-dimethyl- imidodicarbonimidic diamide free base
4. A pharmaceutical composition comprising the compound of formula I as in claim 1.
5. A method of treatment, which can be simultaneously, used as an immunosuppressant and antihyperglycemic agent for the treatment of diabetic nephropathy comprising use of the compound of formula I as in claim 1.
6. A compound of formula I in claim 1, used for the treatment of diabetic nephropathy.
PCT/IN2003/000329 2003-10-07 2003-10-07 Salt of 6-(1, 3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid with n, n-dimethyl-imidodicarbonimidic diamide Ceased WO2005033089A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003272083A AU2003272083A1 (en) 2003-10-07 2003-10-07 Salt of 6-(1, 3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid with n, n-dimethyl-imidodicarbonimidic diamide
PCT/IN2003/000329 WO2005033089A1 (en) 2003-10-07 2003-10-07 Salt of 6-(1, 3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid with n, n-dimethyl-imidodicarbonimidic diamide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2003/000329 WO2005033089A1 (en) 2003-10-07 2003-10-07 Salt of 6-(1, 3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid with n, n-dimethyl-imidodicarbonimidic diamide

Publications (1)

Publication Number Publication Date
WO2005033089A1 true WO2005033089A1 (en) 2005-04-14

Family

ID=34401267

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2003/000329 Ceased WO2005033089A1 (en) 2003-10-07 2003-10-07 Salt of 6-(1, 3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid with n, n-dimethyl-imidodicarbonimidic diamide

Country Status (2)

Country Link
AU (1) AU2003272083A1 (en)
WO (1) WO2005033089A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008003637A3 (en) * 2006-07-05 2008-05-08 Dsm Ip Assets Bv Isolation and use of amine salts of mycophenolic acid
US7683188B2 (en) 2004-04-26 2010-03-23 TEVA Gyógyszergyár Zártkōrūen Mūkōdō Részvénytársaság Process for preparation of mycophenolic acid and ester derivatives thereof
WO2010146604A2 (en) 2009-06-18 2010-12-23 Exemed Pharmaceuticals Processes for preparing metformin hydrochloride

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4948793A (en) * 1987-01-30 1990-08-14 Syntex (U.S.A.) Inc. Treatment of autoimmune diseases with the morpholinoethyl ester of mycophenolic acid, and derivatives thereof
WO2003011273A1 (en) * 2001-07-31 2003-02-13 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Metformin in the treatment of hyperglycemic conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4948793A (en) * 1987-01-30 1990-08-14 Syntex (U.S.A.) Inc. Treatment of autoimmune diseases with the morpholinoethyl ester of mycophenolic acid, and derivatives thereof
WO2003011273A1 (en) * 2001-07-31 2003-02-13 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Metformin in the treatment of hyperglycemic conditions

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7683188B2 (en) 2004-04-26 2010-03-23 TEVA Gyógyszergyár Zártkōrūen Mūkōdō Részvénytársaság Process for preparation of mycophenolic acid and ester derivatives thereof
WO2008003637A3 (en) * 2006-07-05 2008-05-08 Dsm Ip Assets Bv Isolation and use of amine salts of mycophenolic acid
WO2010146604A2 (en) 2009-06-18 2010-12-23 Exemed Pharmaceuticals Processes for preparing metformin hydrochloride

Also Published As

Publication number Publication date
AU2003272083A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
US7638627B2 (en) Process of preparing imatinib and imatinib prepared thereby
US20200383930A1 (en) Benzene-1,3,5-tricarboxamide derived ester lipids and uses thereof
CN1809556A (en) Processes for the preparation of 1-[(benzoimidazole-1yl) quinolin-8-yl] piperidin-4-ylamine derivatives
US12012381B2 (en) Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2010146604A2 (en) Processes for preparing metformin hydrochloride
WO2005023766A1 (en) Salt of atorvastatin with metformin
US8329710B2 (en) Metformin folate and preparation of the same
US6531509B2 (en) Stable gabapentin containing more than 20 ppm of chlorine ion
US8153672B2 (en) Polymorphic forms of deferasirox (ICL670A)
US20030055109A1 (en) Stable gabapentin having pH within a controlled range
US7803942B2 (en) Crystals of morphinan derivative and process for producing the same
AU2001266992A1 (en) Stable gabapentin having pH within a controlled range
WO2005033089A1 (en) Salt of 6-(1, 3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid with n, n-dimethyl-imidodicarbonimidic diamide
AU2016269359B2 (en) Sodium salt of uric acid transporter inhibitor and crystalline form thereof
CA2551501A1 (en) Tolterodine, compositions and uses thereof, and preparation of the same
WO2005033067A1 (en) SALT OF 1,2,6,7,8,8A-HEXAHYDRO-β,δ,6-TRIHYDROXY-2-METHYL-8-[(2S)-2-METHYL-1-OXOBUTOXY]-, (βR,δ R,1S,2S,6S,8S,8AR)- 1-NAPHTHALENEHEPTANOIC ACID WITH N,N-DIMETHYL-IMIDODICARBONIMIDIC DIAMIDE
CN101528696B (en) Crystalline S-(-)-amlodipine anhydrous adipate and preparation method thereof
CN1455770A (en) (2-azabicyclo [2,2,1] hept-7-yl] methanol derivatives as nicotinic acetylcholine receptor agonisis
WO2020068607A1 (en) Process for preparing the compound 2,2-difluoro-n-((1r,2s)-3-fluoro-1-hydroxy-1-(4-(6-(s-methylsulfonimidoyl)pyridin-3-yl)phenyl)propan-2-yl)acetamide
KR101928987B1 (en) A New and Highly Pure Crystalline monohydrate of mirabegron, Method for Preparing or Use Thereof
JPS63255268A (en) Dopamine-beta-hydroxylase inhibitor
US10081605B2 (en) Synthesis of cyclocreatine and analogs thereof
KR860000999B1 (en) Method for preparing N (2,6-dichlorophenyl) acetamine
CN115260107B (en) An anti-tumor drug prodrug, pharmaceutical composition and application in the field of tumor targeted therapy
CN1489578A (en) 3- (3-amidinophenyl) -5- [ ({ [ 1- (1-iminoethyl) -4-piperidyl ] methyl } amino) methyl ] benzoic acid dihydrochloride and preparation method thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP